{
  "abstract": "Introduction The prevalence of OSA is 2.5 times higher in patients with sarcoidosis as compared to matched controls and can have significant impact on fatigue following the treatment. 1 2 Despite increased prevalence screening for OSA in sarcoidosis is not very robust likely due to overlapping symptoms. Through this quality improvement project (QIP), we aimed to enhance OSA screening in patients with sarcoidosis with potential impact of treatment on clinical outcome.Methods As part of this QIP, we conducted retrospective review of clinical data following a baseline audit. Interventions included education of ILD team with the results of baseline audit, latest data about prevalence of OSA in sarcoidosis and to actively screen sarcoidosis patients for OSA with STOP-BANG and Epworth Sleepiness Scale (ESS), at ILD clinic. These patients were then referred to sleep clinic and underwent limited sleep study (LSS) and treatment was offered as per NICE guidelines.Results Baseline audit included 34 patients, 29 (85%) of these patients had BMI of >25 kg/m2. Only 2 of these were screened for OSA and subsequently diagnosed with severe OSA requiring treatment with CPAP. Since the first intervention in January 2025, 23 patients have been screened for fatigue and OSA using STOP-BANG score. Based on screening, 18 (78%) patients were referred for LSS, 10 (43%) patients have so far been diagnosed with OSA. Seven of these patients have moderate to severe OSA (AHI >15). Three patients have started CPAP therapy and four have been advised to make lifestyle changes.Conclusion OSA is under-diagnosed in sarcoidosis. Active screening of sarcoidosis patients for OSA in ILD clinic is feasible utilizing ESS and STOP-BANG scores and results in earlier diagnosis of OSA. It may have potential impact on improving quality of life and fatigue by treatment. This strategy should be considered in a larger multicenter cohort to confirm the co-existence of OSA in sarcoidosis with implications of prompt management.References Roedar M, et al. Journal of Clinical Sleep Medicine 2022;18(10):2415–22.Mari PV, et al. Sarcoidosis, Vasculitis, and Diffuse Lung Diseases 2020;37(2):169.",
  "authors": [
    {
      "affiliations": [
        "Royal Wolverhampton NHS Trust, Wolverhampton, UK"
      ],
      "name": "A Zahid"
    },
    {
      "affiliations": [
        "Royal Wolverhampton NHS Trust, Wolverhampton, UK"
      ],
      "name": "M Sayo"
    },
    {
      "affiliations": [
        "Royal Wolverhampton NHS Trust, Wolverhampton, UK"
      ],
      "name": "A Gulati"
    },
    {
      "affiliations": [
        "Royal Wolverhampton NHS Trust, Wolverhampton, UK"
      ],
      "name": "A Fahim"
    },
    {
      "affiliations": [
        "Royal Wolverhampton NHS Trust, Wolverhampton, UK"
      ],
      "name": "A Mowat"
    }
  ],
  "title": "P53 Obstructive sleep apnea (OSA) in sarcoidosis --- a neglected aspect of the disease",
  "uid": "25c5ace0-7a6f-5695-b13f-9e76369dc265"
}